Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navenibart
- Development stage
- Phase 3
- Lead developer
- Astria Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Navenibart is a humanized monoclonal antibody inhibitor of plasma kallikrein developed for the prevention of hereditary angioedema (HAE) attacks. It is designed to provide long-acting, safe, and effective attack prevention with dosing intervals of every 3 or 6 months. Navenibart works by inhibiting plasma kallikrein activity, thereby reducing the overproduction of bradykinin that leads to HAE attacks. The drug has demonstrated rapid onset and durable efficacy in clinical trials, with reductions in mean monthly attack rates up to 95% and favorable safety/tolerability profiles[1][3][4][5][7]. Developed by Astria Therapeutics (originator Quellis Biosciences), it has received FDA Orphan Drug Designation for HAE.
- Brand names
- navenibart
- Other names
- STAR-0215STAR0215STAR 0215QLS-215QLS215QLS 215
02
Targets
KLKB1 (Plasma kallikrein)
Beyond the preview
Go deeper on navenibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navenibart.